Category: ATHM

  • Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare

    Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare

    Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) announced a multi-year “food is medicine” effort – called the NACHC and Abbott Food for Health Initiative – aimed at making healthy, nutritious food a core part of primary healthcare at Community Health Centers (CHCs) across the U.S.

    Studies show good nutrition is essential for health and plays a critical role in disease prevention and treatment, especially for chronic diseases like diabetes and cardiovascular disease.1 The NACHC-Abbott partnership will include a national certification program designed to help CHCs develop the systems and capacity to advance food for health, along with structured learning, training and knowledge-sharing for CHC staff to build capabilities and expertise in addressing immediate nutrition needs, integrating nutrition into healthcare delivery, and preventing and managing nutrition-related chronic diseases.

    “Since the first health center opened, Community Health Centers – the nation’s largest network of primary care providers – have led the way in addressing food insecurity and integrating nutrition into care delivery,” said Kyu Rhee, MD, MPP, President and CEO, NACHC. “Our collaboration with Abbott builds on that legacy by strengthening Community Health Centers’ capacity to prevent and manage nutrition-related conditions through evidence-based, practical solutions that are designed to improve health outcomes.”

    “We often think about healthcare as what happens in a doctor’s office, but health is also shaped by access to nutritious food and knowledge of the role of food in your health,” said Melissa Brotz, Senior Vice President, Abbott and President of Abbott Fund, the company’s philanthropic foundation. “Food for Health is about bringing those things together – and we’re excited to work with NACHC and Community Health Centers to help make nutrition a core part of how people prevent disease, manage chronic conditions and live healthier.”

    NACHC and Abbott have worked together since 2023 to advance food for health with CHCs. Building on this earlier work, in 2025 NACHC and Abbott assessed CHCs across 37 states to determine what’s working, where gaps exist and what is needed to expand food for health in health centers. This analysis found strong interest in integrating nutrition and care, but fragmented funding, training, data collection and clinical implementation remain key barriers to expanding these efforts across CHCs.

    The NACHC and Abbott Food for Health Initiative was strategically designed to help close these gaps, with a focus on providing CHCs with the support they need to address real-life barriers to nutrition and health in the communities they serve. The framework is made up of three key components:

    • Food for Health Learning Lab, a structured learning program designed to build nutrition literacy and expertise across the CHC workforce, and guide health centers in implementing and measuring food is medicine efforts.
    • Food for Health Community of Practice, a national peer-learning network that will connect health centers to share promising practices, troubleshoot challenges and learn from top experts.
    • Food for Health CORE (Certification of Readiness and Excellence), a voluntary national certification program that will recognize and support CHCs in developing the systems, processes and competencies needed to advance food for health efforts.

    The NACHC and Abbott Food for Health Initiative is a signature program of NACHC’s Center for Nutrition and Health, bringing together public and private partners, CHCs, and other stakeholders. The broader goal of the center is to serve as an innovation hub dedicated to moving food-based clinical care from separate efforts to a coordinated body of programs and policy initiatives that improve health outcomes.

    Frequently Asked Questions

    Q: What is “Food is Medicine”?
    A: Food is Medicine is an approach that recognizes the important role nutrition plays in preventing, managing and treating disease. It focuses on connecting people with nutrition support and healthy food as part of their overall healthcare.

    Q: What is chronic disease?
    A: Chronic diseases are long-term health conditions that often require ongoing care and management. Common examples include heart disease, diabetes and obesity.

    Q: Why is nutrition important to preventing chronic disease?
    A: Good nutrition is a foundation of good health and can play an important role in helping prevent and manage chronic diseases such as diabetes and heart disease. Access to nutritious food, combined with healthcare and education, can help people improve their long-term health and well-being.

    Q: How can Food is Medicine help improve health?
    A: Food is Medicine programs connect nutrition and healthcare to help people make healthier choices, manage chronic conditions and improve overall well-being. Through the NACHC and Abbott Food for Health Initiative, Community Health Centers will have additional tools and support to integrate nutrition into patient care.

    Q: What evidence supports the Food Is Medicine approach?
    A: Research suggests Food is Medicine interventions can improve health outcomes and help reduce healthcare utilization and costs.

    About the National Association of Community Health Centers
    NACHC’s mission is to champion Community Health Centers delivering affordable, effective, comprehensive primary care that is community-driven and improves health for all. For more information, visit www.nachc.org.

    About Abbott
    Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Together with our foundation, Abbott Fund, we partner with trusted organizations to build programs that strengthen care, improve access and help families and communities thrive. We’re committed to building a healthier future by inspiring lifelong habits that support well-being and help to prevent chronic disease for generations to come. Connect with us at Abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

    1 The Role of Nutrition in Chronic Disease (Nutrients, 2023) https://pmc.ncbi.nlm.nih.gov/articles/PMC9921002/

    SOURCE Abbott

  • Can GLP-1s Help People Stop Insulin?

    Can GLP-1s Help People Stop Insulin?

    A new study led by Kasia Lipska, MD, MHS, associate professor of medicine (endocrinology and metabolism) at Yale School of Medicine, examined the impact of Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) therapy on rates of insulin discontinuation in people with type 2 diabetes compared with other oral medications typically prescribed to help manage blood sugar levels. The findings were published in Annals of Internal Medicine.

    While insulin therapy is an effective treatment for many individuals with type 2 diabetes, it can be burdensome to take, requiring daily injections and frequent monitoring, and can result in low blood sugar reactions. Studies have shown that GLP-1RAs can reduce daily insulin requirements, but researchers have yet to determine whether these newer medications can enable safe discontinuation of insulin in people with type 2 diabetes.

    For the study, the researchers used U.S. Department of Veterans Affairs electronic health records data to match 9,000 sets of people based on similar health traits, which they then analyzed by treatment assignment: GLP-1RA, sodium–glucose cotransporter-2 inhibitor (SGLT-2i), or dipeptidyl peptidase-4 inhibitor (DPP-4i). They then retroactively analyzed three years of records to see the rate at which those who started each type of medicine were able to stop using insulin. Insulin discontinuation was measured based on when patients stopped filling their insulin prescriptions at the VA.

    GLP-1RAs performed comparably to the other prescription medicines used to treat diabetes, researchers found. All groups discontinued insulin at a similar rate.

    The results came as a surprise, says Lipska. “I was wondering how big the effect of GLP-1RAs would be, not whether there was any effect at all.”

    Lipska has several ideas as to why the study did not show that GLP-1RA therapy increases the rates of patients stopping insulin therapy. Because the study was not a randomized clinical trial, the data was gathered from routine interactions with clinicians and patients.

    “It’s very complex,” says Lipska. “Patients often add or switch medications over time, so it becomes very difficult to disentangle,” she says.

    Lipska also noted that patients in the study did not advance to a full dose of GLP-1RAs and were using a weaker version than those currently on the market, which may have dampened the effect.

    This study points to a larger issue in diabetes care: There is no standard protocol for discontinuing insulin, Lipska says.

    “Most training for diabetes care is about starting and adjusting dose, not stopping or withdrawing,” says Lipska. She explains that when someone is achieving their target blood sugar numbers and taking incrementally smaller doses, that is usually a cue to stop. Even so, many people with type 2 diabetes remain on insulin, possibly because many clinicians are uncertain about stopping it.

    “The lesson may be that prescribing a GLP-1 receptor agonist is only the first step,” Lipska says. “If we want to help people safely come off insulin, we also need to know when and how to withdraw it. Right now, clinicians have very little guidance for doing that.”

    Other Yale authors of the study include Pradeep Mutalik, MD; Barbara Gulanski, MD, MPH; Mihaela Aslan, PhD; and Lei Yan, PhD.

    Original release: https://medicine.yale.edu/news-article/can-glp-1s-help-people-stop-insulin/

  • Dr. James Greenblatt: Sharing His Views About the Functional Medicine Model of Depression

    Dr. James Greenblatt: Sharing His Views About the Functional Medicine Model of Depression

    Interview by Sheldon Baker

     

    James Greenblatt, MD, is the founder of Psychiatry Redefined, an educational platform dedicated to the personalized, evidence-based treatment of mental health. Psychiatry Redefined offers continuing online education, CME-approved courses, webinars, and a professional fellowship in functional and integrative medicine for mental illness.

    Dr. Greenblatt is also the co-founder of Finally Living Now, a precision functional psychiatry clinic for children and adults.

    A pioneer in the field of integrative medicine, Dr. Greenblatt has treated patients since 1988. After receiving his medical degree and completing his psychiatry residency at George Washington University, he completed a fellowship in child and adolescent psychiatry at Johns Hopkins Medical School. He served as the chief medical officer at Walden Behavioral Care in Waltham, MA for nearly 20 years, and is an assistant clinical professor of psychiatry at Tufts University School of Medicine and Dartmouth College Geisel School of Medicine. An acknowledged integrative medicine expert, educator, and author, Dr. Greenblatt has lectured internationally on the scientific evidence for nutritional interventions in psychiatry and mental illness. Through three decades of practice and research, he is a leading contributor to helping physicians and patients understand the role of personalized medicine for mental illness.

    Dr. Greenblatt is the author of nine books, including the best-seller, Finally Focused: The Breakthrough Natural Treatment Plan for ADHD., his updated edition of Answers to Anorexia, and Functional & Integrative Medicine for Antidepressant Withdrawal, His new book, Finally Hopeful, offers a personalized, whole-body plan to find and fix the root causes of depression. (Altern Ther Health Med. 2026;32(3):4-7).

     

    Sheldon Baker is an InnoVision contributing editor. His freelance editorial content can also be found in several lifestyle publications, and as CEO of Baker Dillon Group LLC, he has created numerous brand marketing communications and public relations campaigns for health and wellness organizations. Contact him at [email protected].

     

    Alternative Therapies in Health and Medicine (ATHM):  Congratulations on your new book, Finally Hopeful.

     

    James Greenblatt, MD: Thank you. Much appreciated.

     

    ATHM: Let’s first look at the difference between your psychiatry model and traditional psychiatry. Can you explain that?

     

    Dr. Greenblatt: Sure. Our current model in conventional psychiatry is really very simple. It’s symptom-based medicine. If someone is sad, they get an anti-sad medicine that we call antidepressants. If they’re anxious, they get an anti-anxiety medication. And functional psychiatry, the core of what I’ve done and the thesis of the book, Finally Hopeful, is looking a little deeper, not just symptomatic treatment, but looking at root cause, be it vitamins, minerals, hormones or gut dysbiosis.

     

    ATHM: How do you describe the difference between integrative and functional psychiatry?

     

    Dr. Greenblatt: That’s a really important question, because integrative medicine has kind of been integrated, for lack of a better word, into our traditional models. We have Harvard and Stanford having programs in mindfulness and yoga. Lifestyle is now a fellowship a doctor can take, and that’s great. Those are great adjuncts, but functional medicine looks at the root cause. It looks at genetics, biochemistry and nutrition. And all too often, integrative medicine doctors or programs just kind of focus on lifestyle and don’t do a deeper dive.

     

    ATHM: Please explain the clinical utility of a functional medicine model of depression, and how your test and treat and model differs from the current traditional model.

     

    Dr. Greenblatt: The functional psychiatry model for depression sees every patient as unique. It’s just not either providing a supplement that might help depression, or medicine. It’s looking at nutritional deficiencies, everything from iron to B12, folate and vitamin D. They all have been shown to contribute to depression. So, we’re looking at nutritional deficiencies, hormones, thyroid, testosterone and the gut, and being able to understand with a genetic analysis what might be contributing to that person’s depression. They are unique and personalized models.

     

    ATHM: Clarify, if you will, dietary, metabolic, genetic, and environmental risk factors for depression, and explain the mechanisms by which these factors influence mood and cognition.

     

    Dr. Greenblatt: As I just mentioned, some of the nutritional deficiencies like B12, folate, zinc and magnesium, are directly responsible for the synthesis of neurotransmitters in the brain. Vitamin D usually being thought of for immune or bone health. But we know vitamin D is the cofactor for the body to make serotonin. So, vitamin D deficiency is directly related to the synthesis of this major neurotransmitter that affects our mood, appetite, and behavior. So much of the functional psychiatry world is looking at these precursors or cofactors that are required for kind of optimal function of the brain and optimal neurotransmitter synthesis.

     

    ATHM: Based on what you’ve said so far, I take it you’re quite a proponent of dietary supplements.

     

    Dr. Greenblatt: Yes, absolutely. Dietary supplements are critical, but I think what a functional psychiatrist does is not just recommend supplements without testing, and that’s the critical piece, that personalized approach, because everyone’s different. Ten patients coming in with depression might have 10 different nutritional deficiencies or metabolic changes that are contributing to their depression.

     

    ATHM: So, how does the integration of nutrition and lifestyle changes impact the treatment of depression?

     

    Dr. Greenblatt: We know some lifestyle interventions, in particular sleep and exercise, have profound effects on mood and depression. There’s not a better antidepressant out there than exercise, and sleep hygiene, directly correlated with depression and even suicide risk. But it’s very hard to tell a depressed patient to just go to the gym or sleep better. The functional psychiatry model digs deeper as to what might be contributing to fatigue and lack of motivation, and what might be interfering with sleep. So, lifestyle is critically important, but it’s usually kind of the icing on the cake and the glue that holds the treatment together hard to be the foundation.

     

    ATHM: Can you further explain the gut-brain network, and how nutrients like vitamin D, B vitamins, magnesium, and others and depression are intertwined.

     

    Dr. Greenblatt: We know that there’s nervous tissue in our gut and actually in our brain, so it’s critically important we call it a two-way street. The brain communicates with the gut and the gut communicates with the brain. The good news is there’s an explosion of research on this gut-brain interaction. I don’t think we have all the details, but a functional psychiatrist can look at gut health, and there are some very clear predictors of the gut, we call dysbiosis, that contribute to anxiety and depression. Not everyone with depression has a gut issue that’s contributing to it. Hence, the model of testing, so we can determine what might be contributing to a person’s depression.

     

    ATHM: How about the role that amino acids play in depression?

     

    Dr. Greenblatt: That’s been really important in my practice for individuals who’ve struggled with multiple approaches, and oftentimes we find low levels of these essential amino acids. We think of amino acids as the building blocks of every protein in the body, and most of the neurotransmitters, serotonin, dopamine, and norepinephrine. Without adequate amino acid precursors, your body just can’t build these neurotransmitters, and we’ve known that research for many years. Sometimes, it’s a diet deficient in amino acids. But more often, it is a problem with digestion and absorption. Patients are eating adequate protein, but they’re not digesting it properly. They don’t have enough acid in their stomach, so they become deficient in amino acids.

     

    ATHM: Explain the mechanisms by which low cholesterol and essential fatty acid intake precipitate depressive pathophysiology.

     

    Dr. Greenblatt: The brain is 60% fat. People are now familiar with fish oil and omega-3s and that has contributed to our understanding of depression both as an augmentation strategy, and as a low dietary omega-3 in the diet contributing to depression. But the other fat that people don’t talk enough about, which we write about and try to help clinicians understand, is low levels of cholesterol in the blood is associated with depression and even suicide risk.

    Everyone is obsessed with lowering your cholesterol, but there’s major mental health implications of a cholesterol level being too low. There are individuals, we believe, who just genetically have very low total cholesterols, under 130. Research has demonstrated those individuals are at higher risk for depression and suicide.

     

    ATHM: But cholesterol being too low is very rarely talked about. Am I correct?

     

    Dr. Greenblatt: I think our cardiologists are obsessed with the lower the number the better. I’ve heard stories of people trying to push total cholesterol under 100, but nobody understands the implications for mental health. Think about cholesterol as the precursor to vitamin D. It’s the precursor to every steroid hormone in the human body and it’s critical for bile acids and digestion, as well as for brain function. We need cholesterol. And most cholesterol is not obtained from our diet. Much to everyone’s disagreement, 85% of cholesterol we make is in our liver. We make it for a purpose. It’s the building blocks of steroid hormones and receptors in the cell membrane in the brain.

     

    ATHM: Discuss the functional differences between pharmaceutical and nutritional lithium and describe biologic mechanisms through which lithium confers neuroprotection.

     

    Dr. Greenblatt: I’ve been studying lithium for many years. It’s fascinating. People think of it as a drug, which is for bipolar illness, but it’s a natural element. It’s on the periodic table. You learn about it in chemistry. It’s critical for technology. Our computer batteries, cell phones, and airplanes all use lithium. My interest has been in lithium as a nutritional supplement. What the research has demonstrated for many years, and recently confirmed, is that lithium is protective of brain health and is translated into studies globally. If you have high lithium in your drinking water, meaning your tap water, you may have lower rates of Alzheimer’s, major mental illness, and suicide. There are lower rates of suicide in those communities. If you have lower lithium, there’s higher rates of suicide. It’s pretty stunning research. That is just often ignored by the medical community.

     

    ATHM: Again, something that’s not really talked about, or at least not much.

     

    Dr. Greenblatt: Not until recently did we get to use the word. Harvard researchers published in the Nature Journal in August of 2025, where they demonstrated that lithium orotate, the supplement that we recommend and talked about for 30 years, actually reversed Alzheimer’s in mice models and prevented Alzheimer’s pathology in mice models. So, it actually broke up the plaques and tangles of Alzheimer’s neuropathology. It was a very incredibly, meticulous study that got a lot of interest, and people are now looking at understanding how we can utilize lithium orotate as a nutritional supplement that we’ve been talking about for 30 years.

     

    ATHM: You have an antidepressant describing plan. How is it helpful with people with depression, or those with antidepressant withdrawal?

     

    Dr. Greenblatt: When we started prescribing antidepressants in the 80s, like Prozac, people thought they were miracle drugs with no side effects. Then, as people tried to stop taking them, coming off these medications, there were significant withdrawal symptoms. It wasn’t for everybody, so it was quite challenging to understand why some people had severe withdrawal, that could be agitation, anxiety, suicidal thoughts, or brain zaps. It had somewhat devastating symptoms for some people. For me, it became clear over the years it wasn’t necessarily the medication, it was what was going on with the patient. By using a functional psychiatry approach, I believe we can almost completely eliminate this antidepressant withdrawal syndrome, because we do the functional medicine testing, replete all the missing micronutrients, and then tapering so withdrawal becomes much simpler, easier, and safer.

     

    ATHM: Depression has many possible causes including psychological, social, lifestyle, medical and biological. Which of those do you feel are the most relevant, or are they all?

     

    Dr. Greenblatt: It’s like picking your favorite child, or dad, or anything else. I think for some, it’s their life story. The trauma becomes critically important. For others, it could be as simple as a B12 deficiency that’s not treated. But usually, a good functional psychiatrist is going to be able to integrate those kinds of psychological, biological, and I would add, genetic vulnerabilities to nutritional deficiencies, or how our neurotransmitters work and are becoming much more important. We now can look at these and understand how to utilize genetics in this integrative and collaborative approach.

     

    ATHM: With all that you’ve said so far, why did you write the book, Finally Hopeful?

     

    Dr. Greenblatt: Well, the title is probably most important to me because as a psychiatrist practicing now for over 30 years, I was hearing too many hopeless stories from parents and families of individuals who didn’t respond to our conventional model of medications and therapy and were giving up hope. Even though much of the work that’s discussed in the book has been known for a while, the reason I wanted to get this book out now is that there’s research to support everything that we discuss. So, this is evidence-based.

    Not that the research is discussed among traditional psychiatrists, and not that our traditional model is looking at blood tests or nutritional deficiencies, but nobody can argue with the research. It’s there. I wanted to offer hope for patients and families, and more importantly, be able to share with my colleagues this is evidence-based science, not alternative medicine.

     

    ATHM: Finally Hopeful can be referred to as a personalized model for patients.

     

    Dr. Greenblatt: Actually, a precision-based model. So, don’t compare what your neighbor is taking for the depression, or your uncle, or anyone else for that matter. It has to be individualized to each person with that model, and I think we can appreciate tremendous improvement in so many patients.

     

    ATHM: Might reading your book change one’s perception of how well antidepressants work, or who they work best for?

     

    Dr. Greenblatt: I think so because my career and the book is not against the use of medications. The model that we’re describing, and the theme, is always how to optimize medications if you need them, how to minimize side effects, or how to taper off them. A nutritional psychiatry, or functional psychiatry, approach will support all those interventions. It’s not either or. Many patients feel they have to choose whether they’re going to take medications, because that’s what their doctor recommends. Or if someone goes to a doctor, perhaps a naturopath or chiropractor, and say they just want to take supplements. So, I think my new book and our model of nutritional psychiatry can be utilized with or without medications.

     

    ATHM: How might a patient advocate for a more personalized treatment plan with their healthcare provider?

     

    Dr. Greenblatt: Good question. Ten years ago, many mental health professionals or psychiatrists would tell patients, there’s no research on nutrition about the gut and it’s just a bunch of hogwash. But now, I think most practitioners are telling their patients there’s a growing amount of research. You should find a practitioner who finds it hard to argue with the research. It’s challenging, I think, to find practitioners knowledgeable in this area. But the first step is to advocate for yourself. Ask your doctor to look at vitamin D, B12 and folate levels. If you need more assistance look for doctors trained in this functional psychiatry model. We just opened a new functional psychiatry clinic, Finally Living Now, that does just that. It is a precision functional psychiatry program with dedicated practitioners who will take patients through the process.

     

    ATHM: I believe you’re one of the experts, if not the utmost expert in this arena. Do other health professionals reach out to you for advice?

     

    Dr. Greenblatt: Absolutely. As I mentioned, this year we were able to organize a collective, virtual clinic called Finally Living Now that’s available nationwide. It’s for clinicians who have gone through additional training in functional psychiatry and have supported their careers by learning. This program helps patients with a functional psychiatry consultation, where they can bring back results to their clinician that they’re working with to support treatment. I just think the message has to be depression is not a lifelong illness. For many, it can be treated and there’s hope.

     

    ATHM: I’m going to read one of your quotes, it’s a little long, but I’d like you to respond to your own words. And that quote is:

     

    Psychiatry can do better, much better, but only if clinicians and their patients take advantage of decades of largely ignored research and clinical results that show depression is not all in your head. The research and results show that many of the root causes of depression are in your body, your digestive system, hormone-producing endocrine system and immune system, and most importantly in your brain, and its connection to all those other systems.

    Can you respond, or maybe even further elaborate on that?

     

    Dr. Greenblatt: Sure. It relates to all the things we’ve been talking about. A slide I sometimes use in my presentations is just a picture of a neck. Anatomy 101 for psychiatry is that we have a neck. What happens in the body affects the brain, and what happens in the brain affects the body. There are many people who benefit from therapy and medications, but there’s at least a third, if not more, that don’t. And for those, I think we have an ethical obligation to dig deeper as medical professionals. We should be looking at hormones that contribute to depression. Also, micronutrients and the gut to understand the role of heavy metals and toxins. As I say in the quote, the research is there, but it’s been ignored. The good news for all of us is now our medical community is appreciating it and continuing the research, and patients are advocating for a different approach and looking to support their health with nutritional supplements. Hopefully, the work that we’re doing is tailored to the individual, not just thrown out the way we typically do with medications.